nach oben

Erschienen in:

16.06.2017 | Review Article

Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis

verfasst von: Ana Gabriela Costa Normando, Camila Lopes Rocha, Isabela Porto de Toledo, Paulo Tadeu de Souza Figueiredo, Paula Elaine Diniz dos Reis, Graziela De Luca Canto, Eliete Neves Silva Guerra

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the capability of biomarkers to predict the risk of oral mucositis in head and neck cancer patients, as well as to assess the correlation between these biomarkers and the severity of mucositis.

Methods

The search was performed at LILACS, PubMed, Science Direct, Scopus, and Web of Science. A search of the gray literature was performed on Google Scholar, OpenGrey, and ProQuest. The methodological quality of the included studies was assessed using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) tool, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system.

Results

After a two-step selection process, 26 studies met the eligibility criteria. In total, 27 biomarkers were evaluated, and the most frequent were the epidermal growth factor (EGF), C-reactive protein (CRP), genetic polymorphisms, tumor necrosis factor alpha (TNF-α), and erythrocyte sedimentation rate (ESR). The meta-analysis showed an expression of polymorphisms in XRCC1 (32.66%), XRCC3 (31.00%), and RAD51 (39.16%) genes, as well as an expression of protein biomarkers (39.57%), in patients with an increased risk of developing oral mucositis.

Conclusions

Dosing biomarkers before starting radiation therapy may be a promising method to predict the risk of developing mucositis and allow radiosensitive patients to have a customized treatment. Although there is currently limited evidence to confirm the putative implementation of serum and salivary biomarkers to assess the correlation between them and the severity of mucositis, this current review provides new research directions.

Nur mit Berechtigung zugänglich

Shield KD, Ferlay J, Jemal A, Sankaranarayanan R et al (2017) The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin 67(1):51–64CrossRefPubMed

Cabrera AR, Yoo DS, Brizel DM (2013) Contemporary radiotherapy in head and neck cancer. Surg Oncol Clin N Am 22(3):579–598CrossRefPubMed

Venkatesh GH, Manjunath VB, Mumbrekar KD et al (2014) Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One 9(3):89079–89079CrossRef

Vera-Llonch M, Oster G, Hagiwara M et al (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106(2):329–336CrossRefPubMed

Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Head Neck 25(12):1057–1070CrossRefPubMed

Villa A, Sonis ST (2015) Mucositis: pathobiology and management. Curr Opin Oncol 27(3):159–164CrossRefPubMed

Scully C, Epstein J, Sonis S (2004) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2. Head Neck 26(1):77–84CrossRefPubMed

Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral

Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45(12):1015–1020CrossRefPubMed

10.

Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025CrossRefPubMed

11.

Jehmlich N, Stegmaier P, Golatowski C et al (2015) Differences in the whole saliva baseline proteome profile associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. J Proteome 125:98–103CrossRef

12.

Strimbu K, Tavel JA (2010) What are biomarkers. Curr Opin HIV AIDS 5(6):463–466. doi:10.1097/COH.0b013e32833ed177 CrossRefPubMedPubMedCentral

13.

Patel S, Ahmed S (2015) Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal 107:63–74CrossRefPubMed

14.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341CrossRefPubMed

15.

Normando AGCN, Rocha CL, de Toledo IP, et al. 2016 Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review. PROSPERO: CRD42016037299. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037299. Accessed September 20, 2016

16.

National Comprehensive Cancer Network. 2016 NCCN clinical practice guidelines in oncology: head and neck cancers (version 2). [Accessed 20 Dec 2016]. Avaliable in: http://www.nccn.org

17.

The Joanna Briggs Institute. (2014). The Joanna Briggs Institute Reviewer’s Manual 2014 Edition: Meta Analysis of Statistics Assessment and Review Instrument (MAStARI) critical appraisal tools Comparable cohort/ Case control studies. Adelaide, Australia: The Joanna Briggs Institute

18.

Higgins JPT, Green S (editors). 2011. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Available from www.handbook.cochrane.org.

19.

Balshem H et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406CrossRefPubMed

20.

Schünemann H et al. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from www.guidelinedevelopment.org/handbook

21.

Akmansu M, Unsal D, Bora H et al (2005) Influence of locoregional radiation treatment on tumor necrosis factor-α and interleukin-6 in the serum of patients with head and neck cancer. Cytokine 31(1):41–45CrossRefPubMed

22.

Ardito F, Giuliani M, Perrone D et al (2016) Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI-TOF/MS. Oral Dis 22(3):209–219CrossRefPubMed

23.

Bonan PRF, Kaminagakura E, Pires FR et al (2007) Histomorphometry and immunohistochemical features of grade I (WHO) oral radiomucositis. Oral Dis 13(2):170–176CrossRefPubMed

24.

Bourton EC, Plowman PN, Smith D et al (2011) Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment. Int J Cancer 129(12):2928–2934CrossRefPubMedPubMedCentral

25.

Christensen ME, Hansen HS, Poulsen SS et al (1996) Immunohistochemical and quantitative changes in salivary EGF, amylase and haptocorrin following radiotherapy for oral cancer. Acta Otolaryngol 116(1):137–143CrossRefPubMed

26.

Goutham HV, Mumbrekar KD, Vadhiraja BM et al (2012) DNA double-strand break analysis by γ-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 84(5):e607–e612CrossRefPubMed

27.

Hamilton S, Yoo J, Hammond A et al (2008) Microvascular changes in radiation-induced oral mucositis. J Otolaryngol Head Neck Surg 37(5):730–737PubMed

28.

Henke M, Bechtold C, Momm F et al (2000) Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radiat Oncol Biol Phys 48(2):339–345CrossRefPubMed

29.

Ho AY, Atencio DP, Peters S et al (2006) Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 65(3):646–655CrossRefPubMed

30.

Ikebe T, Yamasaki K, Takamune Y et al (2012) Reduced expression of nuclear factor kB in oral mucosa undergoing preoperative chemoradiotherapy. Oral Science International 9(2):33–37CrossRef

31.

Krause CE, Otieno BA, Bishop GW et al (2015) Ultrasensitive microfluidic array for serum pro-inflammatory cytokines and C-reactive protein to assess oral mucositis risk in cancer patients. Anal Bioanal Chem 407(23):7239–7243CrossRefPubMedPubMedCentral

32.

Oton-Leite AF, Silva GBL, Morais MO et al (2015) Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients. Lasers Surg Med 47(4):296–305CrossRefPubMed

33.

Popanda O, Marquardt JU, Chang-Claude J et al (2009) Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 667(1–2):58–69CrossRefPubMed

34.

Sonis S, Haddad S, Posner M et al (2007) Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43(3):289–300CrossRefPubMed

35.

Verey F, Nexo E, Greenwood R et al (2011) Trefoil factor family peptides are increased in the saliva of children with mucositis. Clin Chem Lab Med 49(12):2051–2055CrossRefPubMed

36.

Werbrouck J, Duprez F, De Neve W et al (2011) Lack of a correlation between γH2AX foci kinetics in lymphocytes and the severity of acute normal tissue reactions during IMRT treatment for head and neck cancer. Int J Radiat Biol 87(1):46–56CrossRefPubMed

37.

Zou G, Lin X, Wu J et al (2012) Association of serum transforming growth factor-beta1 with radiation injury and survival of patients with early-stage nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 32(8):1171–1174PubMed

38.

Bhattathiri VN, Sreelekha TT, Sebastian P et al (1994) Influence of plasma GSH level on acute radiation mucositis of the oral cavity. Int J Radiat Oncol Biol Phys 29(2):383–386CrossRefPubMed

39.

Chen HW, Chang YC, Lai YL et al (2005) Change of plasma transforming growth factor-beta1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy. Jpn J Clin Oncol 35(8):427–432CrossRefPubMed

40.

Chen HW, Yang SF, Chang YC et al (2008) Epstein-Barr virus infection and plasma transforming growth factor-beta1 levels in head and neck cancers. Acta Otolaryngol 128(10):1145–1151CrossRefPubMed

41.

Chethana RPS, Madathil LP et al (2015) Quantitative analysis of acute phase proteins in post chemo-radiation mucositis. J Clin Diagn Res 9(10):ZC28–ZC31PubMedPubMedCentral

42.

Citrin DE, Hitchcock YJ, Chung EJ et al (2012) Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies. Radiat Oncol 7:64CrossRefPubMedPubMedCentral

43.

Dumbrigue HB, Sandow PL, Nguyen KHT et al (2000) Salivary epidermal growth factor levels decrease in patients receiving radiation therapy to the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89(6):710–716CrossRefPubMed

44.

Ehrsson YT, Hellström PM, Brismar K et al (2010) Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy. Support Care Cancer 18(11):1385–1391CrossRefPubMed

45.

Epstein JB, Emerton S, Guglietta A et al (1997) Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol 33(5):359–363CrossRefPubMed

46.

Epstein JB, Gorsky M, Guglietta A et al (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89(11):2258–2265CrossRefPubMed

47.

Fleckenstein J, Kühne M, Seegmüller K et al (2011) The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 81(5):1465–1472CrossRefPubMed

48.

Gonzalez-Arriagada WA, Ramos LMA, Silva AA et al (2015) Salivary BPIFA1 (SPLUNC1) and BPIFA2 (SPLUNC2 A) are modified by head and neck cancer radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol 119(1):48–58CrossRefPubMed

49.

Handschel J, Prott FJ, Sunderkötter C et al (1999) Irradiation induces increase of adhesion molecules and accumulation of beta(2)-integrin-expressing cells in humans. Int J Radiat Oncol Biol Phys 45(2):475–481CrossRefPubMed

50.

Handschel J, Sunderkötter C, Prott FJ et al (2001) Increase of RM3/1-positive macrophages in radiation-induced oral mucositis. J Pathol 193(2):242–247CrossRefPubMed

51.

Ki Y, Kim W, Nam J et al (2009) C-reactive protein levels and radiation-induced mucositis in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 75(2):393–398CrossRefPubMed

52.

Li P, Du CR, Xu WC et al (2013) Correlation of dynamic changes in gamma-H2AX expression in peripheral blood lymphocytes from head and neck cancer patients with radiation-induced oral mucositis. Radiat Oncol 8:155CrossRefPubMedPubMedCentral

53.

Lundberg M, Saarilahti K, Mäkitie AA et al (2010) TGF beta 1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. Oral Oncol 46(5):369–372CrossRefPubMed

54.

Meirovitz A, Kuten M, Billan S et al (2010) Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer—a prospective pilot study. Radiat Oncol 5:16CrossRefPubMedPubMedCentral

55.

Mohammed FF, Poon I, Zhang L et al (2012) Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer. Head Neck 34(7):985–993CrossRefPubMed

56.

Pratesi N, Mangoni M, Mancini I et al (2011) Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 99(3):356–361CrossRefPubMed

57.

Seyyednejad F, Rezaee A, Haghi S et al (2012) Survey of pre-inflammation cytokines levels in radiotherapy-induced-mucositis. Pak J Biol Sci 15(22):1098–1101CrossRefPubMed

58.

Vuotila T, Ylikontiola L, Sorsa T et al (2002) The relationship between MMPs and pH in whole saliva of radiated head and neck cancer patients. J Oral Pathol Med 31(6):329–338CrossRefPubMed

59.

Wardman P, Folkes LK, Bentzen SM et al (2001) Influence of plasma glutathione levels on radiation mucositis. Int J Radiat Oncol Biol Phys 51(2):460–464CrossRefPubMed

60.

Werbrouck J, Ruyck KD, Duprez F et al (2009) Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 73(4):1187–1195CrossRefPubMed

61.

Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P et al (2008) Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 16(9):1025–1033CrossRefPubMed

62.

Von Bültzingsloöwen I, Brennan MT, Spijkervet FKL et al (2006) Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 14(6):519–527CrossRef

63.

Raber-Durlacher JE, von Bültzingslöwen I, Logan RM et al (2013) Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 21:343–355CrossRefPubMed

Titel: Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis
verfasst von: Ana Gabriela Costa Normando
Camila Lopes Rocha
Isabela Porto de Toledo
Paulo Tadeu de Souza Figueiredo
Paula Elaine Diniz dos Reis
Graziela De Luca Canto
Eliete Neves Silva Guerra
Publikationsdatum: 16.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 9/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3783-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Screening for symptom burden and supportive needs of patients with glioblastoma and brain metastases and their caregivers in relation to their use of specialized palliative care

Erratum to: Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls

Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma

Cardiorespiratory fitness and muscle strength in pancreatic cancer patients

Erratum to: physiotherapy programme reduces fatigue in patients with advanced cancer receiving palliative care: randomized controlled trial

Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie